Prostate cancer screening in Brazil: should it be done or not?
The use of PSA in the screening, detection and prognosis of prostate cancer (PCa) has revolutionized the diagnosis and treatment of this disorder with an increase in detection rates and PCa organ-confined. Despite these benefits and ease of implementation, tracking PCa remains a matter of great controversy. We conducted a literature review and demographic and epidemiological data in Brazil feeling to assess the current state of screening and whether there is justification for population programs. the diferences are valued between developed and underdeveloped countries as the incidence, mortality, screening and access to health. an analysis of the advantages and disadvantages of screening is made as well as a critical analysis of existing studies on screening and some recommendations on a rational screening.
Departamento de Urologia, UNIVALI -Itajai, SC, Brasil.
Wilson F S
WF
Busato
Departamento de Urologia, UNIVALI -Itajai, SC, Brasil.|Instituto Catarinense de Urologia, Itajaí, SC, Brasil.
Gilberto L
GL
Almeida
D001938:Brazil; D055088:Early Detection of Cancer; D006801:Humans; D008297:Male; D008403:Mass Screening; D060787:Neoplasm Grading; D011379:Prognosis; D017430:Prostate-Specific Antigen; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000517:prevention & control / Q000628:therapy*
D017430:Prostate-Specific Antigen
Brazil; Mass Screening; Prostatic Neoplasms